logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Fremanezumab for chronic and episodic migraine

< Back

Fremanezumab for chronic and episodic migraine

Drugs

Neurology and Neurosurgery

October 2017


 
Fremanezumab is a new medicine under development for preventative treatment of chronic and episodic migraine. It acts by targeting a very specific type of protein called the human calcitonin gene-related peptide (CGRP) which is a well-known to be involved in migraine. Therefore, if licensed it will offer a potential new treatment option for patients with migraine.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts